PREDICTORS OF PREGNANCY OUTCOMES IN SLE AND APS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究检查了受试者妊娠至产后三个月期间的妊娠结局。将在受试者妊娠期间和产后期间进行体格检查、尿液和血液检查，并就受试者妊娠情况与受试者进行面谈。还将获得完整的病史。这些信息将用于更好地了解妊娠成功与系统性红斑狼疮（SLE）或抗磷脂综合征（APS）女性低补体缺陷之间的关系。该研究将试图测量以下结局/事件：1）妊娠后12周发生的不明原因的胎儿死亡，2）出院前和早产并发症导致的新生儿死亡，3）36周前指示早产，妊娠期高血压、先兆子痫或胎盘功能不全，和4）宫内生长受限（IUGR），其定义为新生儿出生体重小于胎龄的第10百分位数。此外，该研究还将寻求确定是否在aPL抗体患者的循环和胎盘中检测到经典、替代和终末补体途径激活，并与不良妊娠结局相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study examined pregnancy outcomes over the course of the subject¿s pregnancy through three months postpartum. Physical examinations and urine and blood tests will be conducted during the subject¿s pregnancy and during the postpartum time period, as well as interviews with the subject regarding her pregnancy. A complete medical history will also be obtained. This information will be used to gain a better understanding of the relationship between pregnancy success and low complement deficiencies in women with Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS). The study will seek to measure the following outcomes/events: 1) unexplained fetal death occurring 12 weeks after gestation, 2) neonatal death prior to hospital discharge and due to complications of prematurity, 3) indicated preterm delivery prior to 36 weeks¿ gestation because of gestational hypertension, pre-eclampsia or placental insufficiency, and 4) intrauterine growth restriction (IUGR) which is defined as neonatal birth weight less than the 10th percentile for gestational age. Further, the study will also seek to identify whether classical, alternative, and terminal complement pathway activation will be detected in the circulation and placenta of patients with aPL antibodies, and associated with poor pregnancy outcomes.